Loading...
•
Dec 31, 2023
Fate Therapeutics Q4 2023 Earnings Report
Fate Therapeutics reported Q4 2023 financial results and business updates, highlighting progress in iPSC product platform and clinical programs.
Key Takeaways
Fate Therapeutics reported $1.7 million in revenue for Q4 2023, primarily from preclinical development activities under its collaboration with Ono. The company's cash, cash equivalents, and investments totaled $316.2 million as of December 31, 2023. Clinical development is ongoing across several iPSC-derived cellular immunotherapy programs.
CIRM awarded a $7.9 million grant to support the Phase 1 autoimmunity study of FT819 for systemic lupus erythematosus.
The first patient was treated in the Phase 1 study of FT522, an ADR-armed, CD19-targeted CAR NK cell program.
A Phase 1 study of FT825 / ONO-8250 CAR T-cell program for solid tumors was initiated, incorporating seven synthetic controls.
The company had $316.2 million in cash, cash equivalents, and investments as of December 31, 2023.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Fate Therapeutics is focused on advancing its iPSC product platform in oncology and autoimmunity, with several clinical trials ongoing and initial clinical data expected in 2024.
Positive Outlook
- Strong momentum across the iPSC product platform.
- Award of a grant by CIRM to support Phase 1 clinical investigation of FT819 in systemic lupus erythematosus.
- Treatment of the first patient with FT522, incorporating Alloimmune Defense Receptor technology.
- Initiation of the Phase 1 study of FT825 / ONO-8250 CAR T-cell program in solid tumors.
- Well positioned to generate initial clinical data across off-the-shelf programs during 2024.
Challenges Ahead
- The company’s research and development programs and product candidates may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval.
- Results observed in prior studies of the company’s product candidates, including preclinical studies and clinical trials, may not be observed in ongoing or future studies involving these product candidates.
- There may be a delay or difficulties in the manufacturing of the company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials.
- The company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons.
- Its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects.